---
title: "Strategic Consultancy Report: Siemens Healthineers"
subtitle: "*Consultancy Analysis and Strategic Direction*"
description: "This project is a strategic consultancy report for Siemens Healthineers, a leading global medical technology company. The report provides an in-depth analysis of the company's current market position, competitive landscape, and strategic challenges. It also offers actionable recommendations to enhance Siemens Healthineers' market share and profitability in the rapidly evolving healthcare industry."
categories: [Business Strategy, Year 4]
image: "/projects/business_strategy/business_strategy.jpg"
date: '2025-12-05'
author: 
    - "Cian O'Connor"
    - "Evie Whittaker"
    - "Jack Madden"
    - "Jacob Dean"
    - "Seán Coghlan" 
    - "Martinas Jucys Brady"
    - "Robert Downey"

about:
  template: solana
  links:
    - icon: file-earmark-pdf
      text: Strategic Consultancy Report PDF
      href: projects/business_strategy/business_strategy_consultancy_report.pdf
    - icon: file-earmark-pdf
      text: Strategic Consultancy Report Presentation PDF
      href: projects/business_strategy/business_strategy_presentation.pdf
---

## Executive Summary

This report analyses Siemens Healthineers' strategic position in the global medical technology industry and proposes actions the firm can take to strengthen its long‑term competitiveness. First, the diagnostics stage examines the external environment using PESTEL, Porter's Five Forces, Porter's Value Chain and a VRIO framework. This analysis highlights ageing populations, rising chronic disease, labour shortages and cost pressures as key demand drivers, while strict EU regulations raise compliance and complexity but also create high barriers to entry. Environmental and social pressures, including expectations around circular design and carbon footprints, further reinforce the importance of sustainability and ethical business practices. 

The internal environment of Siemens Healthineers benefits from advanced AI‑enabled technology and platforms, which underpin valuable and hard‑to‑replicate capabilities. Porter's Value Chain shows that heavy investment in developing the business drives high costs but supports differentiation and recurring revenue. Building on the diagnostics, the intervention stage evaluates Siemens Healthineers' current focus on digital transformation as well aligned with sector trends, while exposing vulnerabilities such as the risk of over‑committing to incremental improvements and the complexity of global coordination. 

A Blue Ocean‑inspired strategy is proposed to target less contested markets, particularly modular diagnostics, turning regulations into a competitive advantage by embedding an "ethical‑by‑design" framework that goes beyond compliance to build trust, transparency and ethical goodwill. The intervention also calls for deeper integration of sustainability targets by using digital tools such as predictive analytics to enhance supply‑chain visibility in support of decarbonisation goals. The evaluation section assesses these recommendations across four themes: product and service expansion, sustainability integration, business ethics and partnerships. It concludes that Siemens Healthineers is well equipped to execute these strategies and consolidate its role as a leader in sustainable and digitalised healthcare. 

## Overview and Orientation

Siemens Healthineers is a leading global medical‑technology company specialising in diagnostic imaging and advanced therapy systems. The company enables hospitals and laboratories to diagnose and treat disease more efficiently, generating value through the sale of high‑end equipment, software platforms and long‑term maintenance and upgrade contracts. Strategically, Siemens Healthineers competes through technological leadership, systems integration and partnership‑based business models, underpinned by heavy R&D investment and advanced in‑house manufacturing. 

The operating environment is shaped by rapid technological change, regulatory pressure and shifting healthcare‑delivery models. To remain competitive, the firm has developed capabilities that differentiate it in terms of clinical performance, reliability and integrated solutions. 

This report addresses four key strategic issues:  

1. Leveraging AI and digital capabilities while managing regulatory and ethical risks  
2. Aligning sustainability and decarbonisation goals with cost structures and growth in emerging markets  
3. Improving multinational coordination across R&D, manufacturing and services  
4. Positioning current strategies to capture long‑term value from workforce shortages and the shift to value‑based healthcare  

The remainder of the report is structured into three stages. The diagnostic stage develops a detailed external and internal analysis using PESTEL, Five Forces, VRIO and value‑chain perspectives. The intervention stage investigates Siemens Healthineers' current strategy and explores options such as Blue Ocean moves, ethical‑by‑design AI governance and sustainability‑driven innovation. The evaluation stage then assesses how effectively these directions support sustainable growth, ethical leadership and expanded global healthcare access, offering recommendations for future strategic positioning.  

## Literature Review

Contemporary healthcare literature highlights demographic, technological, regulatory and strategic forces reshaping the global med‑tech market. Ageing populations across OECD and EU economies are significantly increasing demand for diagnostics, imaging and chronic disease management. Persistent healthcare workforce shortages are accelerating the shift towards digital and AI‑enabled diagnostic solutions. Economically, global healthcare spending continues to rise, but manufacturers face sustained cost pressures and value‑based procurement requirements that prioritise efficiency and measurable outcomes.  

Strategically, digital transformation is widely recognised as a core driver of competitive advantage in healthcare organisations. Sustainability research further emphasises the growing relevance of circular‑economy principles in medical‑device design and supply chains. Overall, the literature establishes the external pressures and strategic imperatives shaping value creation in Siemens Healthineers' operating environment.  

## Diagnostic Stage

### PESTEL Analysis

The environment in which Siemens Healthineers operates is shaped by international policy priorities focused on digital transformation, patient safety and ethical innovation. The EU’s ageing population continues to grow, driving demand for chronic‑disease management and long‑term investment in preventive and diagnostic technologies. The EU Medical Device Regulation and In Vitro Diagnostic Regulation impose strict safety, certification and traceability standards, raising compliance complexity and barriers to entry. The EU Artificial Intelligence Act classifies medical AI as “high risk,” requiring transparency and human oversight in diagnostic applications.  

Rising healthcare demand, cost pressures and shifting investment conditions shape the economic context. Global healthcare spending accounted for a substantial share of world GDP in 2022, though fiscal tightening and higher debt‑servicing costs may limit future growth. Inflation, particularly in energy and semiconductor manufacturing, has increased production and logistics costs. Despite this, med‑tech remains attractive, with forecasts indicating sustained growth in medical‑device demand to 2030, driven by ageing populations and chronic‑disease prevalence.  

Demographic and social trends are increasing the importance of diagnostic and imaging solutions. The proportion of older people is growing across OECD countries, and the EU’s median age continues to rise. Ageing is closely associated with chronic and degenerative conditions, while healthcare and long‑term‑care sectors face severe labour shortages, accelerating adoption of AI‑driven and digitally enabled diagnostic technologies.  

Technological innovation is a core driver of Siemens Healthineers’ competitiveness. The sector is undergoing rapid digital transformation, with AI central to improving efficiency and diagnostic precision. Siemens’ platforms, such as AI‑Rad Companion and Syngo Carbon, are designed to reduce clinician workload and enhance clinical accuracy. Established firms benefit from deep integration with healthcare systems and superior access to large‑scale datasets, providing an advantage over startups.  

Environmental sustainability has become a major priority. Healthcare organisations are under pressure to decarbonise operations and supply chains. Circular‑design strategies, including reuse, remanufacturing and recycling, are gaining prominence. With the EU Circular Economy Act expected to come into force, sustainability considerations will become even more important in medical‑device manufacturing.  

Within a complex legal landscape, Siemens Healthineers must comply with strict frameworks that govern data protection and ethical AI. The EU MDR and IVDR require rigorous conformity assessments and certification for medical devices, while the European Data Act and AI Act introduce harmonised rules to protect patient privacy, ensure fair data usage and support trustworthy AI deployment.  

### Porter’s Five Forces

**Threat of new entrants**  
Barriers to entry in the European med‑tech sector are high due to heavy regulation, major capital requirements and extensive R&D needs. Siemens Healthineers' advanced imaging, diagnostics and therapy systems require complex manufacturing, regulatory approvals and established distribution. Strong brand recognition and long‑standing hospital relationships further raise barriers. However, software‑ and AI‑focused startups in digital health may gradually lower entry barriers in some niches.  

**Supplier bargaining power**  
Suppliers include component manufacturers, software providers, consumables producers and contract manufacturers. Siemens Healthineers’ global scale and diversified operations give it strong purchasing power, weakening overall supplier power. Proprietary components such as MRI magnets and PET/CT detectors give some specialised suppliers modest power, but Siemens’ size, global sourcing network and vertical integration significantly limit this risk. Growing reliance on software and data may increase the influence of some suppliers over time.  

**Buyer power**  
Buyers are large organisations such as hospitals and laboratories, which purchase high‑value equipment and negotiate aggressively on pricing, servicing, maintenance, leasing and upgrades. As a result, buyer power is significant. However, Siemens Healthineers’ strong brand reputation and reliability preserve some negotiating power, as buyers prioritise proven performance and service continuity for critical equipment.  

**Threat of substitutes**  
Substitutes include alternative diagnostic methods, outsourced lab services and digital diagnostics that may reduce reliance on traditional imaging and laboratory systems. Regulation and clinical requirements limit rapid substitution, but portable imaging, ultrasound and AI‑based diagnostics can replace some use cases for CT/MRI and other hardware. Siemens Healthineers is investing in AI partnerships and acquisitions to convert this threat into an opportunity.  

**Competitive rivalry**  
Rivalry in the med‑tech sector is intense, with major incumbents such as General Electric and Philips Healthcare alongside thousands of smaller firms. Competition is heightened by moderate market growth and significant price pressure, while differentiation increasingly depends on technology and innovation rather than price alone. Siemens Healthineers’ acquisition of Varian Medical Systems illustrates the importance of scale and portfolio breadth in this competitive environment.  

### VRIO Analysis

Siemens Healthineers possesses technological and organisational resources that provide a strong competitive advantage. Its advanced AI‑enabled diagnostic and imaging platforms, including Syngo Carbon, deliver value by improving efficiency and supporting value‑based healthcare models. As one of the world’s largest med‑tech companies, Siemens Healthineers has capabilities and scale that most competitors cannot easily replicate.  

Embedded relationships with hospitals and health authorities worldwide contribute to inimitability, as partnerships with institutions such as the Ministry of Health in Murcia and other major health systems are difficult for smaller firms to match. The company is structured to capture value through its Value Partnerships framework, which formalises co‑creation with providers and uses KPIs and performance‑based incentives to drive innovation. Operational Excellence programmes, diagnostic‑laboratory automation and a strong presence in public–private partnerships further reinforce a culture focused on long‑term efficiency and transformation.  

Overall, the combination of AI innovation, strategic partnerships and operational capability underpins Siemens Healthineers’ sustained competitive advantage over many med‑tech rivals.  

### Porter’s Value Chain Model

Porter’s Value Chain model analyses a company’s internal operations to identify where value is created and where costs occur. It distinguishes between primary activities—such as inbound logistics, operations, outbound logistics, marketing and sales, and service—and support activities including technology development, HR management and infrastructure. Applying this model to Siemens Healthineers highlights both internal strengths and areas for improvement.  

Inbound logistics are critical because the company relies on expensive and high‑tech components that must be shipped globally. Although this generates high costs, the resulting high‑quality, differentiated products create significant value. Siemens Healthineers invests heavily in operations, particularly R&D, spending large sums annually to develop new and advanced products, which is necessary to maintain a competitive edge. Outbound logistics and installation are complex global processes that incur substantial costs but also support the firm’s reputation as a global brand.  

Recurring sales and contracts, especially in maintenance and upgrades, are a major revenue source. Siemens Healthineers places strong emphasis on marketing and partnerships to increase customer loyalty and create value. Service activities, including maintenance and continuous upgrades, are key value creators but require substantial infrastructure. Support activities such as HR, technological development and procurement reinforce competitive advantage but add significant overheads, illustrating a strategic trade‑off between heavy investment and lean operations.  

## Strategic Intervention

The current strategy of Siemens Healthineers is centred on technological leadership, with major investments in digital transformation and AI. This aligns with global healthcare trends, as multinational firms increasingly view digitalisation as the future of healthcare delivery. Siemens Healthineers aims to lead the digital transformation of the industry and advance remote healthcare solutions, leveraging its strong brand and global trust.  

From a resource‑based view, competitive advantage is driven by internal resources and capabilities. Siemens Healthineers possesses advanced digital technologies, robust R&D infrastructure and highly specialised machinery, all contributing to a sustainable advantage. These technological resources allow the firm to meet evolving healthcare needs while strengthening customer goodwill and trust. From a VRIO perspective, these assets are valuable, rare and difficult to imitate.  

A Blue Ocean strategy is proposed to diversify risk and establish leadership in uncontested markets. One direction is to shift from post‑diagnosis treatment towards pre‑diagnosis monitoring, using AI capabilities to detect early signs of disease and move upstream in the healthcare value chain. While firms such as Huma and AliveCor operate in this space, they lack the scale and R&D capacity of Siemens Healthineers, creating potential for market dominance. Another opportunity lies in emerging markets, where Siemens Healthineers already supports diagnostic access through initiatives such as the Africa Medical Equipment Facility.  

The firm’s growing reliance on medical AI introduces both opportunity and accountability. Under the EU AI Act, medical AI systems are classified as “high‑risk,” subjecting Siemens Healthineers to heightened scrutiny on transparency, data protection and algorithmic bias. To move beyond compliance, the company can embed ethical‑by‑design principles throughout AI development, integrating fairness, explainability and data protection from conception to deployment. This could transform regulation into a strategic advantage and foster trust‑based markets in which safety and integrity are key differentiators.  

The diagnostic analysis also shows that Siemens Healthineers operates in a resource‑intensive, cost‑sensitive environment. Its sustainability report outlines ambitious emissions‑reduction targets, but progress is uneven across regions, with underdeveloped supply chains in emerging markets creating operational and reputational risks. Applying digital and AI capabilities to develop transparent, adaptive supply‑chain systems—using blockchain and predictive analytics for real‑time monitoring of emissions, waste and compliance—could transform sustainability from a reactive cost centre into a proactive source of resilience and value creation.  

Despite recognising ageing populations and rising chronic disease as key demand drivers, Siemens Healthineers’ sustainability strategy is only partially integrated with healthcare‑access objectives. Current efforts focus largely on emissions and product efficiency rather than affordability and accessibility in lower‑income markets, signalling an opportunity gap. By integrating sustainability with inclusive innovation, the firm could develop modular, energy‑efficient diagnostic technologies tailored to infrastructure‑limited systems, better leveraging its digital infrastructure, AI expertise and partnership networks.  

## Evaluation Stage

### Expansion of products and services

Siemens Healthineers already holds a competitive advantage through AI‑enabled diagnostic and imaging platforms such as Syngo Carbon and AI‑Rad Companion, which are deeply integrated into international healthcare systems. Healthcare‑professional shortages and growing demand for scalable, cost‑effective technologies present a clear opportunity to expand offerings and respond to global needs. Partnerships like the Africa Medical Equipment Facility demonstrate successful expansion by enabling affordable, modular solutions in infrastructure‑limited settings.  

There is significant potential to extend a Blue Ocean strategy by collaborating with emerging‑market governments and entering uncontested segments to deliver impactful, sustainable solutions. Siemens Healthineers is well positioned to move beyond AI for post‑diagnosis treatment and develop tools for early detection. By developing modular, cost‑efficient diagnostic products with sustainability at their core, the firm can serve both developed and emerging regions, drawing inspiration from smaller innovators while leveraging its scale.  

### Integration of sustainable practices

The healthcare industry remains a major contributor to the global climate crisis, highlighting the urgency of decarbonisation and circular‑economy adoption. Siemens Healthineers has set ambitious sustainability goals, including steep reductions in Scope 1, 2 and 3 emissions, but these targets are not yet fully synchronised across all regions. This underscores the need for deeper integration of sustainability into diagnostic and intervention strategies.  

In response to regulatory developments such as the EU Circular Economy Act, Siemens Healthineers can embed environmental and social considerations into every product and market strategy. Developing modular, energy‑efficient diagnostic tools and transforming supply chains with blockchain and predictive analytics will enable tracking of emissions and waste across product lifecycles, aligning sustainability with transparency and compliance. This approach can enhance operational resilience, unlock long‑term value and position the company as a pioneer in sustainable healthcare.  

### Strengthening business ethics

Siemens Healthineers operates under an increasingly complex regulatory environment, especially for data protection, patient safety and ethical AI deployment. Frameworks such as the EU MDR and IVDR mandate rigorous conformity assessments, while AI‑driven medical solutions face heightened scrutiny regarding transparency, privacy and algorithmic bias. These challenges classify medical AI as a high‑risk category under EU law.  

The intervention phase highlights an opportunity to progress from basic compliance to proactive ethical innovation. By embedding an ethical‑by‑design framework in every stage of AI development, Siemens Healthineers can turn regulatory demands into a catalyst for trust‑based value creation. This forward‑looking governance can strengthen the firm’s global reputation for safety, integrity and accountability, and provide a powerful source of competitive advantage in a data‑driven healthcare landscape.  

### Building partnerships

The diagnostic stage shows that Siemens Healthineers has a wide‑reaching network of partnerships with hospitals and healthcare ministries worldwide. Through its Value Partnerships framework, it collaborates with institutions such as the Ministry of Health in Murcia and with emerging‑market governments in initiatives like the Africa Medical Equipment Facility. These embedded relationships are difficult to imitate and form a central part of the firm’s operational advantage.  

At the intervention stage, Siemens Healthineers has the opportunity to deepen this network through strategic collaborations that prioritise responsible innovation and align with Blue Ocean ambitions. By co‑developing scalable healthcare‑infrastructure solutions and entering untapped regions, the company can reinforce its position as a transformative partner in global healthcare, break barriers to access and drive sustainable growth across international markets.  

## Consulting Process Reflection

Becoming strategic consultants required the project team to think critically and act as a real‑world consultancy firm working with Siemens Healthineers. Knowledge from lectures and course materials was applied by integrating frameworks such as PESTEL, VRIO and Porter’s Five Forces into a coherent strategic narrative. Through extensive research and use of these frameworks, the group gained insights into Siemens Healthineers’ strategy and the broader med‑tech industry.  

During the diagnostic stage, these frameworks were used to collect and analyse key information and data relating to Siemens Healthineers. Industry reports and literature provided an understanding of the market environment and the client’s position within it, highlighting both sources of strategic advantage and areas of weakness. These insights directly informed the strategic recommendations developed in the intervention stage.  

The intervention stage represented clear progression from diagnosis to solution design, moving from identifying strategic issues to proposing realistic, evidence‑based responses. Recommendations were justified with reference to prior analysis, emphasising the importance of grounding interventions in data rather than assumption. Presenting the work through both a presentation and a written report required clear communication of complex ideas to an audience, reinforcing the importance of balancing creativity with feasibility in strategic consulting.  

## Bibliography
1. Deloitte (2024) 2024 Global Healthcare Outlook. Available at:
https://www.deloitte.com/za/en/Industries/life-sciences-health-care/analysis/global-he
alth-care-outlook.html (Accessed: 30 October 2025).
2. Eurofound (2024) Company practices to tackle labour shortages. Available at:
https://www.eurofound.europa.eu/en/publications/all/company-practices-tackle-labour
-shortages (Accessed: 31 October 2025).
3. European Commission, Eurostat (2025) Population structure and ageing. Available
at:
https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure
_and_ageing#:~:text=On%201%20January%202024%2C%20the,EU's%20population
%20reached%2044.7%20years. (Accessed: 31 October 2025).
4. European Parliament & Council (2017) Regulation (EU) 2017/745 on medical
devices. Official Journal of the European Union. Available at:
https://eur-lex.europa.eu/eli/reg/2017/745/2025-01-10 (Accessed: 31 October 2025).
5. European Parliament & Council (2017) Regulation (EU) 2017/746 on in vitro
diagnostic medical devices. Official Journal of the European Union. Available at:
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746
(Accessed: 31 October 2025).
6. European Parliament & Council (2023) Regulation (EU) 2023/2854 on harmonised
rules on fair access to and use of data ("Data Act"). Official Journal of the European
Union. Available at: https://eur-lex.europa.eu/eli/reg/2023/2854/oj/eng (Accessed: 1
November 2025).
7. European Parliament & Council (2024) Regulation (EU) 2024/1689 of the European
Parliament and of the Council of 13 June 2024 laying down harmonised rules on
artificial intelligence and amending certain Union legislative acts. Official Journal of
the European Union. Available at: https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng
(Accessed: 31 October 2025).
8. Hoveling, T., Nijdam, A.S., Monincx, M., Faludi, J. and Bakker, C. (2024) Circular
economy for medical devices: Barriers, opportunities and best practices from a design
perspective. Resources, Conservation and Recycling. Available at:
https://www.sciencedirect.com/science/article/pii/S0921344924003136 (Accessed: 1
November 2025).
9. IP Business Academy (2025) ‘Lean IP: How Siemens AG Uses Strategic and
Value‑Oriented IP Management to Drive Growth’, IP Business Academy, 10 July.
Available at:
https://ipbusinessacademy.org/lean-ip-how-siemens-uses-strategic-and-value-oriented
-ip-management-to-drive-growth
10. IFC (2023) ‘Siemens Healthineers joins IFC facility to boost access to affordable
medical equipment in Africa’, IFC Pressroom, 15 August. Available at:
https://www.ifc.org/en/pressroom/2023/siemens-healthineers-joins-ifc-facility-to-boos
t-access-to-affordable-medical-equipment-in-africa
11. Imperial Executive Education Digital Transformation in Healthcare: Innovation,
Strategies & Processes. Available at:
https://execed-online.imperial.ac.uk/digital-transformation-in-healthcare
12. KPMG (2024) 2024 Healthcare and Life Sciences Investment Outlook. Available at:
https://kpmg.com/us/en/articles/2024/healthcare-life-sciences-investment-outlook.htm
l#:~:text=Innovations%20in%20cardiology%2C%20robotic%20surgery,deals%20foc
used%20in%20these%20areas. (Accessed: 31 October 2025).
13. KPMG (2018) Medical devices 2030. Available at:
https://kpmg.com/us/en/articles/2023/medical-devices-2030.html (Accessed: 30
October 2025).
14. Lethbridge, J. (2011) Understanding multinational companies in public health
systems, using a competitive advantage framework, PubMed Central. Available at:
https://pmc.ncbi.nlm.nih.gov/articles/PMC3141382/
15. Maresova, P. and Kuca, K. (2014) PORTER´S FIVE FORCES ON MEDICAL
DEVICE INDUSTRY IN EUROPE, MMSL. Available at:
https://www.mmsl.cz/pdfs/mms/2014/04/01.pdf
16. Mazzei, M. (2024) ‘Resource‑Based View (RBV)’, EBSCO Research Starters –
Business & Management. Available at:
https://www.ebsco.com/research-starters/business-and-management/resource-based-vi
ew-rbv
17. MyPOS (2025) ‘What is the Blue Ocean Strategy: meaning, steps and benefits’,
MyPOS Blog – Business Guide. Available at:
https://www.mypos.com/en-gb/blog/business-guide/what-is-the-blue-ocean-strategymeaning-steps-and-benefits
18. OECD (2024) Ageing. Available at:
https://www.oecd.org/en/topics/policy-issues/ageing.html (Accessed: 30 October
2025).
19. Ruan, S. (2020). Research on Strategic Cost Management of Enterprises Based on
Porter’s Value Chain Model. Journal of Physics: Conference Series, 1533(2),
p.022056. doi:https://doi.org/10.1088/1742-6596/1533/2/022056.
20. Siemens Healthineers (no date) ‘Smart Remote Services’, Siemens Healthineers.
Available at:
https://www.siemens-healthineers.com/en-ie/services/customer-services/connect-platf
orms-and-smart-enablers/smart-remote-services
21. Siemens Healthineers AG, 2024. Annual Report 2024. Available at:
https://assets.new.siemens.com/siemens/assets/api/uuid%3Aae46683e-14dd-4455-a88
2-09d4184457c7/Annual-Financial-Report-FY2024.pdf
22. Structures in transition: Facing the challenge of change (2015) Structures in
Transition: Facing the Challenge of Change - Siemens Healthineers Slovakia.
Available at:
https://www.siemens-healthineers.com/sk/magazine/mso-healthcare-business-strategie
s.html (Accessed: 05 November 2025).
23. Subiris, C.R. (2024) VARIAN MEDICAL SYSTEMS’ ACQUISITION BY SIEMENS
HEALTHINEERS - A PRELIMINARY ANALYSIS OF THE TARGET COMPANY.Available at:
https://run.unl.pt/bitstream/10362/172089/1/Group_Personal_WP_file.pdf
24. Sustainability Highlights 2024 (2024) Our Sustainability Report. Available at:
https://www.siemens-healthineers.com/company/sustainability/report (Accessed: 05
November 2025).
25. Teece, D. et al. (2025) Siemens Healthineers: A Digital journey.
doi:10.4135/9781071871348.
26. Wanke, F. (2025) Ai with purpose summit 2025: Siemens’ Vision for industrial-grade
AI | ARC Advisory Group, ARC Advisory Group. Available at:
https://www.arcweb.com/industry-best-practices/ai-purpose-summit-2025-siemens-vis
ion-industrial-grade-ai
27. World Health Organization (2024) Global Spending on health: Emerging from the
pandemic. Available at: https://www.who.int/publications/i/item/9789240104495
(Accessed: 31 October 2025).